The Cancer Genome Atlas (TCGA) [5] analysis of 333 primary prostate tumors revealed BRCA2 and BRCA1 mutation rates that were quite similar to our study (3% and 1%, respectively), while ATM mutations were slightly more frequent than in our study (4% in TCGA vs. 1% in our study). The gene discussed is BRCA2; the disease is prostate neoplasm.